This protocol addresses chronic liver failure occurring in the setting of chronic liver disease complicated by portal hypertension and hepatopulmonary syndrome, specifically in patients with arterial PaO&sub2; below 60 mmHg — representing severe hypoxaemia.
Hepatopulmonary syndrome in the context of portal hypertension and chronic liver disease leads to significant arterial oxygen impairment. Patients with HPS and PaO&sub2; below 60 mmHg require evaluation for liver transplantation, as it represents the only intervention shown to be effective for HPS to date.
The structured regimen for this scenario includes an oxygen-based therapeutic strategy for patients with severe hypoxaemia — a recognised supportive measure in this population. The full protocol specifies the indication criteria, sequencing, and additional management steps.
DOI: 10.1016/j.jhep.2018.03.024
Patients with HPS and PaO2 <60 mmHg should be evaluated for LT since it is the only treatment for HPS that has been proven to be effective to date (II-2;1).
Long-term oxygen therapy is recommended in patients with HPS and severe hypoxaemia. Nevertheless, there is no available data concerning effectiveness, tolerance, cost-effectiveness, compliance and effects on survival rates of this therapy (II-2;1).
View source ↗